Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
09 Agosto 2024 - 6:00AM
Seer, Inc. (Nasdaq: SEER), a leading life sciences company
commercializing a disruptive new platform for proteomics, today
announced that the company will be participating in the upcoming
Canaccord Genuity 44th Annual Growth Conference in Boston, MA.
Seer’s management is scheduled to participate in
a fireside chat on Wednesday, August 14th at 3:00 p.m. Eastern Time
/ 12:00 p.m. Pacific Time. A live webcast of the session will be
available on the Investor section of Seer’s website at
investor.seer.bio. An archived replay will be available on the
company’s website following the conference.
About SeerSeer is a life
sciences company developing transformative products that open a new
gateway to the proteome. Seer’s Proteograph Product Suite is an
integrated solution that includes proprietary engineered
nanoparticles, consumables, automation instrumentation and software
to perform deep, unbiased proteomic analysis at scale in a matter
of hours. Seer designed the Proteograph workflow to be efficient
and easy to use, leveraging widely adopted laboratory
instrumentation to provide a decentralized solution that can be
incorporated by nearly any lab. Seer’s Proteograph Product Suite is
for research use only and is not intended for diagnostic
procedures. For more information, please
visit www.seer.bio.
Investor Contact:Carrie
Mendivilinvestor@seer.bio
Media Inquiries: Patrick
Schmidtpr@seer.bio
Seer (NASDAQ:SEER)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Seer (NASDAQ:SEER)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024